The therapeutic potential of κ-opioids for treatment of pain and addiction.
作者信息
Chavkin Charles
机构信息
Department of Pharmacology, University of Washington School of Medicine, Seattle, WA, USA.
出版信息
Neuropsychopharmacology. 2011 Jan;36(1):369-70. doi: 10.1038/npp.2010.137.
Abstract
摘要
相似文献
1
The therapeutic potential of κ-opioids for treatment of pain and addiction.κ-阿片类药物在疼痛治疗和成瘾治疗方面的治疗潜力。
Neuropsychopharmacology. 2011 Jan;36(1):369-70. doi: 10.1038/npp.2010.137.
2
International Narcotics Research Conference (INRC) 2006.2006年国际麻醉品研究会议
IDrugs. 2006 Oct;9(10):693-5.
3
Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials.用于精神疾病的κ-阿片受体拮抗剂：从实验室到临床试验
Depress Anxiety. 2016 Oct;33(10):895-906. doi: 10.1002/da.22500.
4
Selective kappa opioid antagonists for treatment of addiction, are we there yet?用于治疗成瘾的选择性κ阿片受体拮抗剂，我们做到了吗？
Eur J Med Chem. 2017 Dec 1;141:632-647. doi: 10.1016/j.ejmech.2017.10.012. Epub 2017 Oct 10.
5
Targeting opioid receptors: A new treatment for brain disorders.靶向阿片受体：一种治疗脑部疾病的新方法。
CNS Neurol Disord Drug Targets. 2010 Apr;9(2):128. doi: 10.2174/187152710791012116.
6
Kappa Opioid Receptor Antagonists as Potential Therapeutics for Stress-Related Disorders.κ 阿片受体拮抗剂作为应激相关障碍的潜在治疗药物。
Annu Rev Pharmacol Toxicol. 2020 Jan 6;60:615-636. doi: 10.1146/annurev-pharmtox-010919-023317.
7
Kappa opioid receptor signaling in the brain: Circuitry and implications for treatment.大脑中的κ阿片受体信号传导：神经回路及其治疗意义。
Prog Neuropsychopharmacol Biol Psychiatry. 2015 Oct 1;62:51-60. doi: 10.1016/j.pnpbp.2015.01.001. Epub 2015 Jan 12.
8
Role of kappa-opioid receptors in stress and anxiety-related behavior.κ-阿片受体在应激和焦虑相关行为中的作用。
Psychopharmacology (Berl). 2013 Oct;229(3):435-52. doi: 10.1007/s00213-013-3195-5. Epub 2013 Jul 9.
9
Antagonists of the kappa opioid receptor.κ 阿片受体拮抗剂。
Bioorg Med Chem Lett. 2014 May 1;24(9):2021-32. doi: 10.1016/j.bmcl.2014.03.040. Epub 2014 Mar 24.
10
Addiction to prescription opioids: characteristics of the emerging epidemic and treatment with buprenorphine.处方阿片类药物成瘾：新出现的流行情况特征及丁丙诺啡治疗
Exp Clin Psychopharmacol. 2008 Oct;16(5):435-41. doi: 10.1037/a0013637.
引用本文的文献
1
Efficacy and safety of anrikefon in patients with pruritus undergoing haemodialysis: multicentre, double blind, randomised placebo controlled phase 3 trial.安立克芬用于血液透析瘙痒患者的疗效和安全性：多中心、双盲、随机、安慰剂对照3期试验
BMJ. 2025 Aug 19;390:e085208. doi: 10.1136/bmj-2025-085208.
2
G Protein Inactivation as a Mechanism for Addiction Treatment.G蛋白失活作为成瘾治疗的一种机制。
Biol Psychiatry. 2025 Apr 4. doi: 10.1016/j.biopsych.2025.03.021.
3
Stereoselective Synthesis and Biological Evaluation of Perhydroquinoxaline-Based κ Receptor Agonists.基于全氢喹喔啉的κ受体激动剂的立体选择性合成及生物学评价
Int J Mol Sci. 2025 Jan 24;26(3):998. doi: 10.3390/ijms26030998.
4
Recommended Opioid Receptor Tool Compounds: Comparative for Receptor Selectivity Profiles and for Pharmacological Antinociceptive Profiles.推荐的阿片受体工具化合物：受体选择性概况及药理镇痛概况的比较
ACS Pharmacol Transl Sci. 2024 Dec 31;8(1):225-244. doi: 10.1021/acsptsci.4c00604. eCollection 2025 Jan 10.
5
G protein Inactivation as a Mechanism for Addiction Treatment.G蛋白失活作为成瘾治疗的一种机制。
bioRxiv. 2024 Dec 17:2024.12.16.628727. doi: 10.1101/2024.12.16.628727.
6
Activation of kappa opioid receptor suppresses post-traumatic osteoarthritis via sequestering STAT3 on the plasma membrane.κ 阿片受体的激活通过将 STAT3 隔离在质膜上抑制创伤后骨关节炎。
Cell Commun Signal. 2024 Jun 18;22(1):335. doi: 10.1186/s12964-024-01709-4.
7
GPCR-G protein selectivity revealed by structural pharmacology.结构药理学揭示的 G 蛋白偶联受体-蛋白选择性。
FEBS J. 2024 Jul;291(13):2784-2791. doi: 10.1111/febs.17049. Epub 2024 Jan 8.
8
Temporally specific gene expression and chromatin remodeling programs regulate a conserved enhancer.时间特异性基因表达和染色质重塑程序调节保守增强子。
Elife. 2023 Nov 8;12:RP89993. doi: 10.7554/eLife.89993.
9
Effects of the novel selective κ-opioid receptor agonist NP-5497-KA on morphine-induced reward-related behaviors.新型选择性 κ 阿片受体激动剂 NP-5497-KA 对吗啡诱导的奖赏相关行为的影响。
Sci Rep. 2023 Oct 24;13(1):18164. doi: 10.1038/s41598-023-45584-4.
10
The Kappa Opioid Receptor Agonist 16-Bromo Salvinorin A Has Anti-Cocaine Effects without Significant Effects on Locomotion, Food Reward, Learning and Memory, or Anxiety and Depressive-like Behaviors.κ 阿片受体激动剂 16-溴-Salvinorin A 具有抗可卡因作用，而对运动、食物奖励、学习和记忆、焦虑和抑郁样行为没有显著影响。
Molecules. 2023 Jun 19;28(12):4848. doi: 10.3390/molecules28124848.
本文引用的文献
1
Ligand-directed c-Jun N-terminal kinase activation disrupts opioid receptor signaling.配体定向的 c-Jun N 端激酶激活破坏阿片受体信号转导。
Proc Natl Acad Sci U S A. 2010 Jun 22;107(25):11608-13. doi: 10.1073/pnas.1000751107. Epub 2010 Jun 3.
2
Kinase cascades and ligand-directed signaling at the kappa opioid receptor.κ 阿片受体的激酶级联和配体定向信号转导。
Psychopharmacology (Berl). 2010 Jun;210(2):137-47. doi: 10.1007/s00213-010-1806-y. Epub 2010 Apr 17.
3
The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system.压力中的烦躁不安成分是由强啡肽κ-阿片系统的激活所编码的。
J Neurosci. 2008 Jan 9;28(2):407-14. doi: 10.1523/JNEUROSCI.4458-07.2008.
4
Long-acting kappa opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase.长效κ阿片受体拮抗剂通过激活c-Jun氨基末端激酶破坏受体信号传导并产生非竞争性效应。
J Biol Chem. 2007 Oct 12;282(41):29803-11. doi: 10.1074/jbc.M705540200. Epub 2007 Aug 16.
5
Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses.κ阿片受体拮抗作用和前强啡肽基因破坏可阻断应激诱导的行为反应。
J Neurosci. 2003 Jul 2;23(13):5674-83. doi: 10.1523/JNEUROSCI.23-13-05674.2003.
6
Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats.κ-阿片受体拮抗剂在大鼠强迫游泳试验中的抗抑郁样作用
J Pharmacol Exp Ther. 2003 Apr;305(1):323-30. doi: 10.1124/jpet.102.046433.
7
Kappa-opioid receptors and analgesia.κ-阿片受体与镇痛作用
Trends Pharmacol Sci. 1990 Feb;11(2):70-6. doi: 10.1016/0165-6147(90)90321-x.
Zotero 插件